Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results
Dec 15, 2025, 07:16 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and new analysis explores whether pharmaceutical manufacturing is truly moving back onshore.